Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies
Abstract
Pregnancy induces profound metabolic adaptations, including marked rises in lipid concentrations. Triglyceride levels may increase by 100-300% compared with pre-pregnancy values, and in some women this physiological response exceeds the adaptive range. Although triglyceride elevation alone does not necessarily increase the risk of complications, higher triglyceride levels have been linked to maternal disorders such as preeclampsia, gestational hypertension, and acute pancreatitis, as well as adverse fetal outcomes, including abnormal birth weight and preterm delivery. Management of hypertriglyceridemia in pregnancy is challenging due to limited pharmacologic options and the need to ensure fetal safety. A personalized, multidisciplinary strategy-based on a low-fat diet, weight optimization, and regular physical activity-remains first-line therapy. In severe hypertriglyceridemia with imminent pancreatitis risk, rapid interventions such as pharmacotherapy or therapeutic plasma exchange are required to promptly reduce triglyceride levels. Novel agents targeting apolipoprotein C-III (olezarsen, volanesorsen) can lower triglycerides by 40-70%, but their safety in pregnancy is not established. While olezarsen is not recommended, two case reports describe successful and safe use of volanesorsen in pregnant women with familial chylomicronemia syndrome under close monitoring. This narrative review synthesizes current evidence on the pathophysiology, prognostic implications, and…
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.